OTLK Stock Forecast & Price Target

Outlook Therapeutics is supported by a meaningful turnaround in ONS-5010 after winning its FDA appeal in May 2026 and resubmitting its BLA on June 1, 2026, with a PDUFA decision expected within 60 days of receipt, strengthening the case for U.S. approval and commercialization by the end of calendar 2026. Commercial momentum is also building around LYTENAVA, which is already launched in the U.K., Germany, and Austria, with management guiding to first-year U.S. sales of $50 million to $75 million and more than $500 million in annual U.S. sales by 2030. Although Q3 FY26 revenue was still only about $0 million and the company ended Fiscal 3Q26 with roughly $62.3 million in pro forma cash, the combination of an FDA-approved ophthalmic bevacizumab, expanding payer engagement, and a focused launch strategy underpins a favorable fundamental outlook.

Outlook Therapeutics is a high-risk clinical-stage biotech whose lead asset ONS-5010 has failed to secure FDA approval after three separate Complete Response Letters on August 30, 2023, August 28, 2025, and December 31, 2025, signaling a persistent regulatory overhang. Although NORSE TWO met its safety and efficacy endpoints, the first two reviews were derailed by CMC issues, manufacturing inspection observations, and lack of substantial evidence, while the third CRL again cited insufficient effectiveness data and requested additional confirmatory evidence. With only EU and U.K. marketing authorization for LYTENAVA and repeated U.S. setbacks, the company faces a weak commercialization path, heightened execution risk, and continued uncertainty around whether its core pipeline can translate clinical progress into meaningful revenue.